RESUMEN
Affecting an estimated 88 million Americans, prediabetes increases the risk for developing type 2 diabetes mellitus (T2DM), and independently, cardiovascular disease, retinopathy, nephropathy, and neuropathy. Nevertheless, little is known about the use of metformin for diabetes prevention among patients in the Veterans Health Administration, the largest integrated healthcare system in the U.S. This is a retrospective observational cohort study of the proportion of Veterans with incident prediabetes who were prescribed metformin at the Veterans Health Administration from October 2010 to September 2019. Among 1,059,605 Veterans with incident prediabetes, 12,009 (1.1%) were prescribed metformin during an average 3.4 years of observation after diagnosis. Metformin prescribing was marginally higher (1.6%) among those with body mass index (BMI) ≥35 kg/m2, age <60 years, HbA1c≥6.0%, or those with a history of gestational diabetes, all subgroups at a higher risk for progression to T2DM. In a multivariable model, metformin was more likely to be prescribed for those with BMI ≥35 kg/m2 incidence rate ratio [IRR] 2.6 [95% confidence intervals (CI): 2.1-3.3], female sex IRR, 2.4 [95% CI: 1.8-3.3], HbA1c≥6% IRR, 1.93 [95% CI: 1.5-2.4], age <60 years IRR, 1.7 [95% CI: 1.3-2.3], hypertriglyceridemia IRR, 1.5 [95% CI: 1.2-1.9], hypertension IRR, 1.5 [95% CI: 1.1-2.1], Major Depressive Disorder IRR, 1.5 [95% CI: 1.1-2.0], or schizophrenia IRR, 2.1 [95% CI: 1.2-3.8]. Over 20% of Veterans with prediabetes attended a comprehensive structured lifestyle modification clinic or program. Among Veterans with prediabetes, metformin was prescribed to 1.1% overall, a proportion that marginally increased to 1.6% in the subset of individuals at highest risk for progression to T2DM.
Asunto(s)
Trastorno Depresivo Mayor , Diabetes Mellitus Tipo 2 , Metformina , Estado Prediabético , Veteranos , Femenino , Humanos , Persona de Mediana Edad , Estudios de Cohortes , Trastorno Depresivo Mayor/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/diagnóstico , Hipoglucemiantes/uso terapéutico , Metformina/uso terapéutico , Estado Prediabético/tratamiento farmacológico , Estado Prediabético/epidemiología , Prescripciones , Estudios RetrospectivosRESUMEN
Peripheral neuropathy (PN) is a significant public health concern, resulting in abnormal gait biomechanics, diminished postural stability, and increased risk of falls. A wearable tactile feedback system previously developed for sensory augmentation of prosthetic limbs has been adapted for individuals with PN and evaluated in a pilot group of 4 participants with idiopathic bilateral PN, as well as one with Charcot-Marie-Tooth Disease. Participants were assessed both for their abilities to perceive tactile stimuli, and for the effect of tactile biofeedback on their gait. Preliminary data indicate that most participants could localize tactile stimuli and make meaningful modifications to their gait in real time, but that the effect of feedback on gait was highly variable from subject to subject, demanding further investigation.